Metropolis Healt
Metropolis Healt Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Metropolis anticipates adding approximately 300 more collection centres in the rest of the year. Organic growth for Metropolis Healthcare remains strong, with patient volumes and test volumes growing around 6% organically.
From Metropolis Healt's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Metropolis anticipates adding approximately 300 more collection centres in the rest of the year.
- Core Diagnostics acquisition is expected to contribute to growth; initial year focused on business clean-up with revenue growth to accelerate from year 2.
- Consolidated volume growth is projected at double-digit rates (10%-11%) for the remainder of the year.
- Organic growth remains strong at around 12%, with no immediate price hikes planned.
- From FY '27 onwards, potential to increase growth to mid-teens percent annually as new collection centres and acquisitions scale up.
- Clinical trial business is a small but growing segment, contributing positively.
2 more points from Metropolis Healt's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Metropolis Healt said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major lab expansion was completed last year; current focus is on investing in collection centres.
- Plan to increase collection centres by approximately 300 more this year.
- Most new service centres will be added through franchisee route; only top 5-6 cities will have company-owned centres.
- Aim to increase collection centres per lab to 30 within the next 12 to 18 months.
- Focus on boosting productivity and accelerating organic growth over the next 6 to 9 months.
2 more points from Metropolis Healt's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Metropolis Healt said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Metropolis Healt's call on order book
Pro opens every point from 15K+ earnings calls
Metropolis Healt — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹425 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Metropolis Healt's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
Others in Healthcare Services this season
- 3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Indegene Ltd (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
- Yatharth Hospital & Trauma Care Services Ltd (Q2 FY26)
Mature hospitals have room to increase occupancy to 75%, supporting margin and revenue growth. Key concall takeaways from Yatharth Hospital & Trauma Care…
- Rainbow Childrens Medicare Ltd (Q2 FY26)
Capital expenditures were INR 260.6 crores in the recent quarter towards expansion, enhancement, and acquisitions (Guwahati and Warangal hospitals). Key…
Arthneeti Pro · Annual
Metropolis Healt and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Metropolis Healt Q2 FY26 results?
Metropolis anticipates adding approximately 300 more collection centres in the rest of the year. Organic growth for Metropolis Healthcare remains strong, with patient volumes and test volumes growing around 6% organically.
What is Metropolis Healt share price analysis?
Metropolis Healt currently shows a neutral. The stock trades at a P/E of 52.9 with a market cap of ₹11,002 Cr. Investors should review the full earnings analysis for detailed insights.
Is Metropolis Healt planning capital expenditure?
Major lab expansion was completed last year; current focus is on investing in collection centres.
Keep Metropolis Healt on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.